MIRM - Company ID 0001759425
The table below shows Mirum Pharmaceuticals, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$228.76M | -$1.96M | $15.21M | -$18.77M | -$39.67M | -$25.21M |
| Capital expenditure | $664.00K | $41.00K | $13.00K | $41.00K | $0.00 | $3.00K |
| Investing cash flow | -$11.57M | -$16.13M | -$13.00K | $27.02M | $36.50M | -$32.78M |
| Dividends paid | - | - | - |
Mirum Pharmaceuticals, Inc. reported operating cash flow of $55.83M for fiscal year 2025. That is up 440.7% from $10.32M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow grew from -$39.36M (FY 2019) to $55.83M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $270.08M | $6.36M | $1.21M | $12.99M | $18.10M | $6.59M |